In a significant policy shift, President Trump's administration recently rescheduled marijuana at the federal level. While this move has sparked national discussions, it also raises important questions about how Pennsylvania's DUI laws will be affected.

The Shift from Schedule I to Schedule III

Under Pennsylvania law, specifically 75 Pa.C.S. § 3802(d)(1), it was previously possible to prosecute individuals simply for having marijuana metabolites in their blood, regardless of actual impairment, because marijuana was classified as a Schedule I controlled substance. Now, with marijuana rescheduled to a Schedule III substance, this automatic “metabolite-only” prosecution is no longer viable. Prosecutors must now demonstrate actual impairment, not just the presence of marijuana traces.

Implications for DUI Cases

This change is a game-changer for DUI law in Pennsylvania. It means that simply having THC metabolites in one's system is not enough for a DUI conviction. Defense attorneys, like Attorney Paul Aaroe, can argue more robustly that the presence of marijuana does not equal impairment, and prosecutors will have to rely on clear evidence of impaired driving behavior.

Practical Outcomes and Legal Strategies

For drivers, this means a fairer approach that focuses on actual impairment rather than mere biological traces. For legal practitioners, it underscores the importance of staying updated on how DUI laws evolve with changing federal classifications. It also means that the burden of proof will shift more heavily onto demonstrating real-time impairment, rather than relying solely on the presence of a metabolite.